首页 / 院系成果 / 成果详情页

Genomic profiling and associated B cell lineages delineate the efficacy of neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma 期刊论文

编号：

4E4A26775BEAB1BA094FCA6A79185C04
作者：

Zhang, Hongyu^[1];Wen, Haoyu^[1];Zhu, Qiaoliang(祝巧良)^[1]Zhang, Yuchen^[1];Xu, Fengkai(胥丰恺)^[1]Ma, Teng^[1];Guo, Yifan^[1];Lu, Chunlai(卢春来)^[1]Zhao, Xuelian^[2];Ji, Yuan(纪元)^[2]Wang, Zhiqiang^[5];Chu, Yiwei(储以微)^[5]Ge, Di(葛棣)^[1]Gu, Jie(古杰)^[1]Liu, Ronghua(刘荣花)^[3,4]
语种：

英文
期刊：

EBIOMEDICINE ISSN：2352-3964 2024 年 100 卷 ; FEB
收录：
关键词：

Oesophageal squamous cell carcinoma Immunotherapy B cells MMR
摘要：

Background Neoadjuvant chemoimmunotherapy has offered novel therapeutic options for patients with locally advanced oesophageal squamous cell carcinoma (ESCC). Depicting the landscape of genomic and immune profiles is critical in predicting therapeutic responses. Methods We integrated whole-exome sequencing, single -cell RNA sequencing, and immunofluorescence data of ESCC samples from 24 patients who received neoadjuvant treatment with PD-1 inhibitors plus paclitaxel and platinum-based chemotherapy to identify correlations with therapeutic responses. Findings An elevation of small insertions and deletions was observed in responders. DNA mismatch repair (MMR) pathway alternations were highly frequent in patients with optimal responses and correlated with tumour infiltrating lymphocytes (TILs). Among the TILs in ESCC, dichotomous developing trajectories of B cells were identified, with one lineage differentiating towards LMO2+ germinal centre B cells and another lineage differentiating towards CD55+ memory B cells. While LMO2+ germinal centre B cells were enriched in responding tumours, CD55+ memory B cells were found to correlate with inferior responses to combination therapy, exhibiting immune-regulating features and impeding the cytotoxicity of CD8+ T cells. The comprehensive evaluation of transcriptomic B cell lineage features was validated to predict responses to immunotherapy in patients with cancer. Interpretation This comprehensive evaluation of tumour MMR pathway alternations and intra-tumoural B cell features will help to improve the selection and management of patients with ESCC to receive neoadjuvant chemoimmunotherapy. Copyright (c) 2024 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
推荐引用方式
GB/T 7714：

Zhang Hongyu,Wen Haoyu,Zhu Qiaoliang, et al. Genomic profiling and associated B cell lineages delineate the efficacy of neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma [J].EBIOMEDICINE,2024,100.
APA：

Zhang Hongyu,Wen Haoyu,Zhu Qiaoliang,Zhang Yuchen,&Liu Ronghua.(2024).Genomic profiling and associated B cell lineages delineate the efficacy of neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma .EBIOMEDICINE,100.
MLA：

Zhang Hongyu, et al. "Genomic profiling and associated B cell lineages delineate the efficacy of neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma" .EBIOMEDICINE 100(2024).
入库时间：

2025/2/19 11:42:25
更新时间：

2025/2/21 12:42:40

浏览次数：6  下载次数：0

分享到：

浏览次数：6

下载次数：0

打印次数：0